Deliver Your News to the World

Final Zenacort data made available to public.


(WEBWIRE.COM) Feb. 13, 2007 New York, NY - Innovative Laboratories, the makers of Zenacort, a new weight loss supplement, have made available to the public, positive results from a recent 12 week study.

A 200-subject, double-blind, placebo-controlled, 5 arm clinical trial of top rated weight loss supplements was performed. In the study more than 50% of obese patients in the Zenacort treatment group experienced 10 percent or more total body weight loss during the latest 12-week study period. Mean weight loss in the Zenacort group was 20.1 lbs., compared to 4.8 lbs in the placebo group p is less than 0.0001 and 10.2 lbs average from the balance of the test group representing other products. Importantly, the rate of weight loss for patients in the Zenacort group had not plateaued by the end of the study. Zenacort was well-tolerated with a study completion rate of 92 percent versus a completion rate of 62% for the placebo group and 85% for the balance of the test groups.

The study was a double-blind, randomized, placebo-controlled study comparing the top weight loss supplements to placebo. Primary and secondary efficacy measurements in the study all showed that Zenacort was significantly better than placebo and better than all other active agents in all control groups.

This trial involved 200 subjects, 159 women and 41 men with an average age of 40 and a mean body mass index BMI of 38. A BMI of greater then 30.0 is classified as obese per guidelines from the U.S. Department of Health and Human Services. Each subject in the study received daily doses, consisting of Zenacort, placebo, or one of the other top rated brands separately. Subjects were asked to reduce caloric intake by 500 calories per day.



This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.